Rg3 also sensitizes prostate cancer cells to docetaxel and other chemotherapeutics by inhibiting cell growth and inducing apoptosis via inhibition of NF-κB signaling pathway (24). This evidence concerns the gene NFKB1 and prostate carcinoma.